论文信息 - Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog® - 字舞流文

Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®

R. Vigersky | J. Sturis | B. Grosman | Gayane Voskanyan | O. Cohen | Natalie Kurtz | M. Ekelund | Anirban Roy | Neha Parikh | Di Wu